6:08 PM
 | 
Feb 27, 2013
 |  BC Extra  |  Company News

Vertex unveils Phase III details for breakthrough combo

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) unveiled details late Tuesday for its Phase III program to evaluate cystic fibrosis (CF) drug Kalydeco ivacaftor plus VX-809 in CF patients who are homozygous for the delta F508 mutation in the CF transmembrane conductance regulator ( CFTR) gene. The combination treatment and Kalydeco as monotherapy were the first products to receive breakthrough drug designation from FDA, which Vertex announced in January. The news sent shares of Vertex up $2.79 to $46.97 on Wednesday,...

Read the full 390 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >